EUCTR2012-005796-14-AT
Active, not recruiting
Phase 1
A randomized, pilot study to assess the impact of single nucleotide polymorphisms in the ABCB1 and ABCG2 genes on brain and organ distribution of dual Pgp/BCRP substrates in humans. - Polymorphisms 11C-inhibitor
Overview
- Phase
- Phase 1
- Intervention
- Not specified
- Conditions
- The effect of genetic polymorphisms on drug distribution will be investigated in healthy volunteers
- Sponsor
- Medizinische Universität Wien
- Enrollment
- 60
- Status
- Active, not recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Sex: female and male
- •Age: 18 \- 65 years old
- •Normotensive after 5 min rest in a supine position
- •Normofrequent after 5 min rest in a supine position
- •No disease interferring with the study objectives (at investigators discretion)
- •Ability to comprehend the full nature and purpose of the study, including possible risks and side effects
- •Volunteers must sign the informed consent prior to inclusion in the study
- •No contraindication for MRI
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
Exclusion Criteria
- •Any abnormality found as part of the pretreatment screening or in any of the laboratory tests performed that the investigators considers clinically relevant
- •Presence of any other ECG abnormality which the investigator considers clinically relevant
- •Intake of any medication, which the investigator considers may affect the validity of the study, due to interference with CYP3A4, Pgp or BCRP (Pgp inductors such as St. John’s wort, rifampicin or inhibitors such as esomeprazol, omeprazol, pantoprazol, lansoprazol, atrovastatin, itraconazol) or may cause potential harm to the subject (e.g. drug\-drug interaction between tariquidar and loperamide or quinidine)
- •Contraindication to arterial cannulation (e.g. treatment with anticoagulants such as phenprocoumon or LMW heparines).
- •Participation in the evaluation of any drug within two weeks before the study day.
- •History of drug and alcohol abuse.
- •Blood donation within 1 month before the start of the study
- •Participation in clinical studies with exposure to radiation exceeding the allowed maximum foreseen by the current guidelines (http://ec.europa.eu/energy/nuclear/radioprotection/publication/doc/136\_en.pdf).
- •Pregnancy or breastfeeding (female subjects)
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
study to test the effect of music on quality of life of cancer patients undergoing chemotherapyHealth Condition 1: D499- Neoplasm of unspecified behavior of unspecified siteCTRI/2023/03/050509Apollo Proton Cancer Centre
Not yet recruiting
Not Applicable
To Investigate whether resveratrol and copper can reduce the amount of virus load in patients with Chronic Hepatitis B and C virus infectioHealth Condition 1: B191- Unspecified viral hepatitis BCTRI/2023/05/053055Tata Memorial Hospital
Not yet recruiting
Not Applicable
A prospective pilot study evaluating the effects of a clinically-supervised weight loss intervention programme combined with behavioural change strategy in morbidly obese adults in SingaporeObesityPublic Health - Health service researchDiet and Nutrition - ObesityACTRN12612000163808Hanniel Han Rong LIM40
Completed
Not Applicable
A pilot trial to assess the effect of a structured communication approach on quality of life in secure mental health settingsISRCTN34145189Canterbury Christ Church University (UK)96
Active, not recruiting
Phase 1
Study to evaluate the efficacy of OnabotulinumtoxinA in migraineEUCTR2017-002866-38-ITIRCCS FONDAZIONE ISTITUTO NEUROLOGICO NAZIONALE C. MONDINO42